Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Proc Natl Acad Sci U S A Retrieve available abstracts of 37 articles: HTML format

Single Articles

June 2025
1. WANG M, Wang Y, Pan X, Wang B, et al
   Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2500019122.
   PubMed     Abstract available
   
   
   
2. GORELIK A, Paulo JA, Schroeter CB, Lad M, et al
   CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.
   Proc Natl Acad Sci U S A. 2025;122:e2424985122.
   PubMed     Abstract available
   
   
   May 2025
3. WANG H, Huang J, Zhang Z, An Y, et al
   Phase separation of RXRgamma drives tumor chemoresistance and represents a therapeutic target for small-cell lung cancer.
   Proc Natl Acad Sci U S A. 2025;122:e2421199122.
   PubMed     Abstract available
   
   
   
4. JIAO Z, Zhang M, Ning J, Yao H, et al
   The oncoprotein SET promotes serine-derived one-carbon metabolism by regulating SHMT2 enzymatic activity.
   Proc Natl Acad Sci U S A. 2025;122:e2412854122.
   PubMed     Abstract available
   
   
   April 2025
5. GONG JR, Lee J, Han Y, Cho KH, et al
   DDX54 downregulation enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden.
   Proc Natl Acad Sci U S A. 2025;122:e2412310122.
   PubMed     Abstract available
   
   
   
6. YIN L, Zhang J, Zhu Z, Peng X, et al
   The FBXW7-KMT2 axis in cancer-associated fibroblasts controls tumor growth via an epigenetic-paracrine mechanism.
   Proc Natl Acad Sci U S A. 2025;122:e2423130122.
   PubMed     Abstract available
   
   
   March 2025
7. BALTANAS FC, Kramer-Drauberg M, Garcia-Navas R, Patrucco E, et al
   SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS(G12D) inhibitor in KRAS LUAD.
   Proc Natl Acad Sci U S A. 2025;122:e2422943122.
   PubMed     Abstract available
   
   
   
8. SAXENA T, Quan A, Chan E, Kozlova N, et al
   EGFR-induced lncRNA TRIDENT promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair.
   Proc Natl Acad Sci U S A. 2025;122:e2415389122.
   PubMed     Abstract available
   
   
   January 2025
9. ZHANG Y, Wang X, Gu Y, Liu T, et al
   Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells.
   Proc Natl Acad Sci U S A. 2025;122:e2420005122.
   PubMed     Abstract available
   
   
   December 2024
10. MEI J, Jiang J, Li Z, Pan Y, et al
    Increased perfluorooctanoic acid accumulation facilitates the migration and invasion of lung cancer cells via remodeling cell mechanics.
    Proc Natl Acad Sci U S A. 2024;121:e2408575121.
    PubMed     Abstract available
    
    
    
11. CHEN J, Wang T, Zhang D, Wang H, et al
    KDM5D histone demethylase mediates p38alpha inactivation via its enzymatic activity to inhibit cancer progression.
    Proc Natl Acad Sci U S A. 2024;121:e2402022121.
    PubMed     Abstract available
    
    
    November 2024
12. ZHAO H, Beyett TS, Jiang J, Rana JK, et al
    Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity.
    Proc Natl Acad Sci U S A. 2024;121:e2417144121.
    PubMed     Abstract available
    
    
    October 2024
13. ZHU J, Du W, Zeng Y, Liu T, et al
    CD73 promotes non-small cell lung cancer metastasis by regulating Axl signaling independent of GAS6.
    Proc Natl Acad Sci U S A. 2024;121:e2404709121.
    PubMed     Abstract available
    
    
    
14. MCGUIRE CK, Meehan AS, Couser E, Bull L, et al
    Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors.
    Proc Natl Acad Sci U S A. 2024;121:e2317694121.
    PubMed     Abstract available
    
    
    
15. DAVIS E, Avniel-Polak S, Abu-Kamel S, Antman I, et al
    Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications.
    Proc Natl Acad Sci U S A. 2024;121:e2405001121.
    PubMed     Abstract available
    
    
    September 2024
16. FUJIWARA Y, Takahashi RU, Saito M, Umakoshi M, et al
    Oncofetal IGF2BP3-mediated control of microRNA structural diversity in the malignancy of early-stage lung adenocarcinoma.
    Proc Natl Acad Sci U S A. 2024;121:e2407016121.
    PubMed     Abstract available
    
    
    
17. FERNANDEZ-GARCIA F, Fernandez-Rodriguez A, Fustero-Torre C, Pineiro-Yanez E, et al
    Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.
    Proc Natl Acad Sci U S A. 2024;121:e2402913121.
    PubMed     Abstract available
    
    
    July 2024
18. SHAN L, Wang W, Du L, Li D, et al
    SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.
    Proc Natl Acad Sci U S A. 2024;121:e2401834121.
    PubMed     Abstract available
    
    
    
19. LARA-SAEZ I, Mencia A, Recuero E, Li Y, et al
    Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.
    Proc Natl Acad Sci U S A. 2024;121:e2322917121.
    PubMed     Abstract available
    
    
    June 2024
20. KUMARI P, Tarighi S, Fuchshuber E, Li L, et al
    SIRT7 promotes lung cancer progression by destabilizing the tumor suppressor ARF.
    Proc Natl Acad Sci U S A. 2024;121:e2409269121.
    PubMed     Abstract available
    
    
    
21. RUAN ML, Ni WX, Chu JCH, Lam TL, et al
    Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers.
    Proc Natl Acad Sci U S A. 2024;121:e2316615121.
    PubMed     Abstract available
    
    
    
22. YANG C, Ma S, Zhang J, Han Y, et al
    EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2317790121.
    PubMed     Abstract available
    
    
    May 2024
23. FERRARONE JR, Thomas J, Unni AM, Zheng Y, et al
    Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase.
    Proc Natl Acad Sci U S A. 2024;121:e2403685121.
    PubMed     Abstract available
    
    
    
24. DONG Z, Wang Y, Xu G, Liu B, et al
    Genetic and phenotypic profiling of single living circulating tumor cells from patients with microfluidics.
    Proc Natl Acad Sci U S A. 2024;121:e2315168121.
    PubMed     Abstract available
    
    
    
25. DUTT P, Haider N, Mouaaz S, Podmore L, et al
    beta-catenin turnover is regulated by Nek10-mediated tyrosine phosphorylation in A549 lung adenocarcinoma cells.
    Proc Natl Acad Sci U S A. 2024;121:e2300606121.
    PubMed     Abstract available
    
    
    March 2024
26. HAN X, Wang D, Yang L, Wang N, et al
    Activation of polyamine catabolism promotes glutamine metabolism and creates a targetable vulnerability in lung cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2319429121.
    PubMed     Abstract available
    
    
    February 2024
27. JANSEN RA, Mainardi S, Dias MH, Bosma A, et al
    Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.
    Proc Natl Acad Sci U S A. 2024;121:e2319492121.
    PubMed     Abstract available
    
    
    January 2024
28. CHEN NY, Lin CW, Lai TY, Wu CY, et al
    Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.
    Proc Natl Acad Sci U S A. 2024;121:e2313397121.
    PubMed     Abstract available
    
    
    
29. WU XN, Li JY, He Q, Li BQ, et al
    Targeting the PHF8/YY1 axis suppresses cancer cell growth through modulation of ROS.
    Proc Natl Acad Sci U S A. 2024;121:e2219352120.
    PubMed     Abstract available
    
    
    December 2023
30. LEE H, Jung JH, Ko HM, Park H, et al
    RNA-binding motif protein 10 inactivates c-Myc by partnering with ribosomal proteins uL18 and uL5.
    Proc Natl Acad Sci U S A. 2023;120:e2308292120.
    PubMed     Abstract available
    
    
    October 2023
31. CHUNG YH, Ortega-Rivera OA, Volckaert BA, Jung E, et al
    Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2221859120.
    PubMed     Abstract available
    
    
    
32. IM SJ, Obeng RC, Nasti TH, McManus D, et al
    Characteristics and anatomic location of PD-1(+)TCF1(+) stem-like CD8 T cells in chronic viral infection and cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2221985120.
    PubMed     Abstract available
    
    
    
33. GINN L, Maltas J, Baker MJ, Chaturvedi A, et al
    A TIAM1-TRIM28 complex mediates epigenetic silencing of protocadherins to promote migration of lung cancer cells.
    Proc Natl Acad Sci U S A. 2023;120:e2300489120.
    PubMed     Abstract available
    
    
    September 2023
34. SUAREZ JS, Novelli F, Goto K, Ehara M, et al
    HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.
    Proc Natl Acad Sci U S A. 2023;120:e2307999120.
    PubMed     Abstract available
    
    
    
35. CHEN Y, Shi J, Wang X, Zhou L, et al
    An antioxidant feedforward cycle coordinated by linker histone variant H1.2 and NRF2 that drives nonsmall cell lung cancer progression.
    Proc Natl Acad Sci U S A. 2023;120:e2306288120.
    PubMed     Abstract available
    
    
    
36. LIN X, Chen Y, Lin L, Yin K, et al
    mitoSplitter: A mitochondrial variants-based method for efficient demultiplexing of pooled single-cell RNA-seq.
    Proc Natl Acad Sci U S A. 2023;120:e2307722120.
    PubMed     Abstract available
    
    
    
37. YOUSEFI M, Andrejka L, Szamecz M, Winslow MM, et al
    Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
    Proc Natl Acad Sci U S A. 2023;120:e2303224120.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.